Eliem Therapeutics, Inc. (ELYM) - Forward P/S Multiple

Corporate company logo of Eliem Therapeutics (ELYM)

The forward price-to-sales ratio demonstrates the pricing power of Eliem Therapeutics (ELYM) within the chronic pain therapy segment, where the mark reflects the asset's current valuation. The business is currently integrating an acquired immune drug development system, temporarily limiting external transactions. The ultimate goal is a large-scale expansion of its neuropharmaceutical presence through successful clinical trials and the capture of market niches.

ELYM Eliem Therapeutics Inc.: Forward Price to Sales in the range 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for Eliem Therapeutics Inc. (ELYM)

- current price and projected stock value:
Initial company analysis:Eliem Therapeutics (ELYM)
Original product of eliemtx.com

To identify fundamental benchmarks in the financial reporting of Eliem Therapeutics (ELYM), it is critical to evaluate market value relative to projected revenues. This expected price-to-sales ratio measures the premium on future sales, allowing investors to use chart analysis to separate speculative noise from the actual capitalization of CNS biotech projects implemented by management under strict compliance protocols.

Competitors of Eliem Therapeutics

Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cyclerion.com CYCN|Forward P/S Multiple PTIX|KTTA - Market Cap to Future Revenue Ratio|Forward P/S Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics Inc (ATXI) - Market Cap to Future Revenue Ratio|BCLI - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio caratherapeutics.com|CHRO: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple